Kindred Biosciences (NASDAQ: KIN) recently received a number of ratings updates from brokerages and research firms: 3/13/2019 – Kindred Biosciences was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating. 3/11/2019 – Kindred Biosciences was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating. 3/7/2019 – […]